AlphaCentric Advisors’s Trillium Therapeutics Inc. TRIL Stock Holding History

AlphaCentric Advisors’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-54,500	Closed	-$957K	–	286
2021 Q3	$957K	Buy	54,500 +24,500	+82%	+$286K	0.24%	34
2021 Q2	$291K	Buy	+30,000	New	+$282K	0.08%	93
2020 Q4	–	Sell	-500	Closed	-$7K	–	240
2020 Q3	$7K	Hold	500	–	–	﹤0.01%	160
2020 Q2	$4K	Buy	+500	New	+$3.09K	﹤0.01%	141

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

AlphaCentric Advisors's TRIL Position: Q4 2021 in Review

AlphaCentric Advisors sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 54,500 shares — an estimated $957K sold.

AlphaCentric Advisors first reported a position in TRIL in Q2 2020 and held it in 4 quarters. The position peaked at $957K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

AlphaCentric Advisors reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
AlphaCentric Advisors sold 54,500 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $957K.
AlphaCentric Advisors first reported a position in Trillium Therapeutics Inc. in Q2 2020 and held it in 4 quarters.
AlphaCentric Advisors's Trillium Therapeutics Inc. position peaked at $957K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.